Meta and Google Back $1.8 Billion AI Biology Bet

Corporate cash continues chasing specialized compute models outside standard enterprise cloud suites. Benzinga reported that Meta Platforms and Google have invested $300 million into a $1.8 billion artificial intelligence biology venture backed by Mark Zuckerberg, doubling down on machine learning applications for life sciences. The venture push arrives even as equity positioning stays defensively structured. Big tech's balance sheet commitments keep deploying into specialized model development, but public market dealer books are not absorbing price swings with open arms. Instead, the major indices remain trapped under their zero-gamma levels, leaving dealers in short gamma territory where structural hedging tends to press moves rather than buffer them. SPY trades at 776.84, pinned just beneath its gamma flip of 777.31. That tight boundary keeps market makers positioned to sell intraday weakness and chase intraday strength, with the put wall providing immediate support lower down at 775 and the call wall overhead at 781. QQQ sits in an identical operational regime at 757.43, operating under its flip of 759.43 with its put wall at 755 and call wall at 765. The options market is currently pricing a daily expected move of plus or minus 0.65% in SPY and 0.9% in QQQ. While venture capital flows into life sciences AI architectures, public tape liquidity lacks the shock-absorbing insulation of positive dealer gamma. Until spot crosses back over the flip lines across both index complexes, dealer order flow remains a volatility amplifier on any macro shift rather than a stabilizing bid.